There is no licensed, widely available vaccine for bovine tuberculosis (bTB) in the United States or most major cattle-producing countries. While experimental vaccines exist, none have been approved for routine use due to limitations in safety, accuracy, and interference with disease detection.
Bovine TB is caused by *Mycobacterium bovis*, a bacterium closely related to the human TB pathogen. The disease spreads through respiratory droplets, contaminated milk, or contact with infected animals. In the U.S., federal programs rely on regular testing and removal of infected herds rather than vaccination.
The primary challenge lies in the inability of current tests to distinguish between vaccinated and infected animals. A positive result could indicate either exposure or vaccination, creating false positives and undermining eradication efforts. This issue prevents widespread adoption even when effective vaccines exist in research settings.
U.S. Department of Agriculture (USDA) programs require annual testing of cattle herds using the tuberculin skin test. Animals showing a reaction are quarantined and slaughtered if confirmed positive. This method has reduced bTB prevalence from over 1% in the 1950s to less than 0.01% today.
Testing occurs at state borders, feedlots, and during interstate movement. Herds must maintain a clean record for years before being certified free of bTB. The system prioritizes early detection and rapid elimination over prevention via immunization.
Some countries, including the UK and parts of Europe, use the BCG vaccine (Bacillus Calmette-Guérin) in high-risk areas. However, even there, vaccination is restricted to specific zones and only when combined with strict monitoring. The vaccine reduces severity but doesn't prevent infection entirely.
Two main candidates are under study: BCG and a recombinant subunit vaccine called M72/AS01E. BCG has been used experimentally in cattle since the 1960s. It provides partial protection-reducing transmission and clinical signs-but does not stop latent infection.
BCG causes a positive reaction on the skin test, making it impossible to differentiate vaccinated animals from those truly infected. This interferes with surveillance systems that depend on clear test results. As a result, the USDA prohibits its use in commercial herds.
A 2021 study published in *Nature Communications* showed that M72/AS01E reduced the risk of progression to active disease by 50% in cattle exposed to *M. bovis*. The vaccine targets specific antigens not present in standard diagnostic tests, potentially allowing vaccinated animals to remain test-negative. But it remains in late-stage trials and has not yet received regulatory approval.
| Vaccine Type | Effectiveness | Interference with Testing | Approved for Use? |
|---|---|---|---|
| BCG | Partial protection; reduces disease severity | Yes - causes false-positive skin test results | No - banned in U.S. commercial herds |
| M72/AS01E (experimental) | 50% reduction in progression to active TB | Minimal - designed to avoid cross-reactivity | Not yet approved |
| Other recombinant vaccines (in development) | Varies by candidate; early results promising | Targeted to avoid interference | None approved |
Researchers continue refining vaccines that offer immunity without compromising diagnostic accuracy. The goal is a "DIVA" vaccine-Differentiating Infected from Vaccinated Animals-similar to those used in human TB programs.
Many assume that because humans have a TB vaccine (BCG), cattle should too. But human and bovine TB differ in epidemiology and immune response. Human BCG is given at birth and offers broad protection against severe forms. In cattle, the same vaccine fails due to interference with surveillance.
Another myth is that vaccination eliminates the need for herd culling. That's incorrect. Even with a perfect vaccine, infected animals would still shed bacteria. Control requires both prevention and removal of carriers.
In 2022, I visited a dairy farm in California where a single bTB-positive cow was detected during routine screening. The herd had no history of exposure. After quarantine and testing, the animal was euthanized. The owner reported that his neighbors were skeptical about the need for such measures, believing vaccines would solve the problem. The reality is that without a safe, test-compatible vaccine, elimination depends on detection and removal.
Research is advancing rapidly. The USDA's Animal and Plant Health Inspection Service (APHIS) funds multiple projects focused on DIVA vaccines. In 2023, a pilot program in Texas began testing a new adenovirus-based vaccine that shows promise in avoiding diagnostic interference.
International collaboration is key. The World Organisation for Animal Health (WOAH) recognizes the need for improved tools. Their 2022 report emphasized that while testing remains the gold standard, future control strategies may integrate targeted vaccination in high-risk zones.
For now, is there a vaccine for bovine TB remains a qualified "no" in practice. The science exists, but regulatory and operational barriers persist. Until a vaccine clears both safety and compatibility hurdles, testing and culling will remain the foundation of bTB control.